Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy.
作者信息
Viljoen L, Acaba J, Agbassi Y J P, Beko B, Goslett C, Hoddinott G, Kumar B, Kumar R G, McKenna L, Moses G, Sachs T, Seidel S, von Delft A
机构信息
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
The BENEFIT Kids Community Advisory Board (CAB), Asia Pacific Council of AIDS Service Organizations, Bangkok, Thailand.
出版信息
Int J Tuberc Lung Dis. 2023 Sep 1;27(9):655-657. doi: 10.5588/ijtld.23.0164.
Abstract
摘要
相似文献
1
Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy.社区对耐多药结核病儿童适宜药物的看法：重要性、优先事项及宣传
Int J Tuberc Lung Dis. 2023 Sep 1;27(9):655-657. doi: 10.5588/ijtld.23.0164.
2
Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children.儿童耐多药结核病治疗的药代动力学和安全性研究现状。
Int J Tuberc Lung Dis. 2018 May 1;22(5):15-23. doi: 10.5588/ijtld.17.0355.
3
Multidrug-resistant tuberculosis in children: Are the same therapy options available worldwide?儿童耐多药结核病：全球是否有相同的治疗选择？
Int J Infect Dis. 2023 May;130 Suppl 1:S16-S19. doi: 10.1016/j.ijid.2023.03.023. Epub 2023 Mar 21.
4
Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.脊柱耐多药结核病——是否意味着终结的开始？对 25 例培养证实的耐多药结核脊柱患者的研究。
Spine (Phila Pa 1976). 2009 Oct 15;34(22):E806-10. doi: 10.1097/BRS.0b013e3181af7797.
5
Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.获取治疗耐药结核病的新药物：患者、提供者和社区的观点。
Int J Infect Dis. 2015 Mar;32:56-60. doi: 10.1016/j.ijid.2014.12.012.
6
Drug-resistant tuberculosis: pediatric guidelines.耐药结核病：儿科指南。
Pediatr Infect Dis J. 2011 Jun;30(6):501-5. doi: 10.1097/INF.0b013e31820b583d.
7
Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.对氟喹诺酮类药物和链霉素耐药但对二线注射治疗敏感的耐多药结核病，其预后比广泛耐药结核病更好。
Clin Infect Dis. 2009 Mar 1;48(5):e50-2. doi: 10.1086/597010.
8
Pediatric drug-resistant tuberculosis: a global perspective: a global perspective.儿童耐多药结核病：全球视角。
Paediatr Drugs. 2011 Dec 1;13(6):349-55. doi: 10.2165/11593160-000000000-00000.
9
Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.了解个体化治疗时长在耐多药和广泛耐药结核病中的个人观点。
Am J Respir Crit Care Med. 2014 Aug 15;190(4):374-83. doi: 10.1164/rccm.201402-0363PP.
10
Overcoming challenges in the diagnosis, prevention, and treatment of pediatric drug-resistant tuberculosis.克服儿童耐多药结核病诊断、预防和治疗方面的挑战。
Expert Rev Respir Med. 2017 May;11(5):385-394. doi: 10.1080/17476348.2017.1309294. Epub 2017 Mar 28.
引用本文的文献
1
Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries.氯法齐明片剂在三个高负担国家耐利福平结核病儿童中的可接受性。
IJTLD Open. 2025 Aug 13;2(8):478-485. doi: 10.5588/ijtldopen.25.0309. eCollection 2025 Aug.
本文引用的文献
1
Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field.稳定的、配制的贝达喹啉混悬液，以支持在现场实施儿科剂量方案。
Int J Tuberc Lung Dis. 2023 Mar 1;27(3):189-194. doi: 10.5588/ijtld.22.0440.
2
Extemporaneously compounded liquid formulations of clofazimine.氯法齐明的临时配制的液体配方。
Int J Tuberc Lung Dis. 2023 Feb 1;27(2):106-112. doi: 10.5588/ijtld.22.0331.
3
Paediatric formulations for the treatment of drug resistant TB: closing the gaps.用于治疗耐药结核病的儿科制剂：填补空白
Int J Tuberc Lung Dis. 2022 Dec 1;26(12):1097-1100. doi: 10.5588/ijtld.22.0498.
4
Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape.10 个耐多药结核病高负担国家在联合国 HLCM 宣言发布 2 年后的形势分析：变化中的进展与挫折。
Int J Infect Dis. 2021 Jul;108:557-567. doi: 10.1016/j.ijid.2021.06.022. Epub 2021 Jun 15.
5
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB.左氧氟沙星、莫西沙星和利奈唑胺在接受结核病治疗的儿童和青少年中的可接受性。
Int J Tuberc Lung Dis. 2020 Dec 1;24(12):1316-1318. doi: 10.5588/ijtld.20.0544.
6
Factors influencing diagnosis and treatment initiation for multidrug-resistant/rifampicin-resistant tuberculosis in six sub-Saharan African countries: a mixed-methods systematic review.影响撒哈拉以南非洲六国耐多药/利福平耐药结核病诊断和治疗启动的因素：一项混合方法系统评价。
BMJ Glob Health. 2020 Jul;5(7). doi: 10.1136/bmjgh-2019-002280.
7
Pretomanid: First Approval.苯并异噻唑酮（pretomanid）：首次批准。
Drugs. 2019 Nov;79(16):1797-1803. doi: 10.1007/s40265-019-01207-9.
8
Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children.儿童耐多药结核病治疗的药代动力学和安全性研究现状。
Int J Tuberc Lung Dis. 2018 May 1;22(5):15-23. doi: 10.5588/ijtld.17.0355.
9
Household context and psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa.南非夸祖鲁-纳塔尔省儿童耐多药结核病的家庭背景和心理社会影响。
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):40-46. doi: 10.5588/ijtld.17.0371.
Zotero 插件